Integrated Vital Medical Dynamics, LLC

Improving the lives of patients and those who care for them

Heparin Infusion Management References

Digital Intern Knowledge Base

This Documentation is intended to accompany the Digital Intern Heparin Educator and Digital Intern Heparin Infusion Management module and is meant to support and explain the recommendations made by those products. This information is not meant to provide medical advice, inform medical decisions, or be used in any way other than in conjunction with Digital Intern products. If you are a medical professional caring for a patient, you must always rely on your own training, expertise, and judgment to determine if the Digital Intern recommendations are appropriate for your patient.

If you are not using the Digital Intern learn more about it here.

 

This Knowledge Base entry contains references only.

If your organization subscribes to the Digital Intern Heparin Infusion Management module, you may access a version of the full article through the links in the help text of Digital Intern recommendations. The latest version is available through the Knowledge Base with an iVMD Knowledge Base account. If you have an account, Log in. If you do not have an account, but your organization subscribes to the Digital Intern, Create an Account.

References:

  1. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. CHEST 2012;141:419s-494s.
  2. Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. CHEST 2012;141:24s-43s.
  3. Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. CHEST 2012; 141:576s-600s.
  4. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016; 41:32-67.
  5. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support. J Heart Lung Transplant. 2013(2):157-89.
  6. Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg. 2014;118(4):731-743.
  7. Jneid H, Anderson JL, Wright AR, et al. 2012 ACCF/AHA Focused update of the guideline for the management of patients with unstable angina/Non-ST elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2012;126:875-910.
  8. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction: Executive Summary: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127:529-555.
  9. Amsterdam EA, Wenger NK, Brindis RG, et al. ACC/AHA guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344–e426.
  10. Smith ML and Wheeler KE. Weight based heparin protocol using antifactor Xa monitoring. Am J Health-Syst Pharm. 2010;67:371-374
  11. Rosborough TK. Monitoring unfractionated heparin therapy with anti-Xa activity results in fewer monitoring tests and dosages changes thank monitoring with the activated partial thromboplastin time. Pharmacotherapy. 1999;19:760-6.
  12. Guervil DJ. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45:861-8.
  13. Van Roessel S, Middeldorp S, Cheung YW, Zwinderman AH, de Pont AC. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin. Neth J Med. 2014; 72(6):305-10.
  14. Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013; 47(2):151-58.
  15. Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time. Pharmacotherapy. 1999; 19(6):760-66.
  16. Faust AC, Kanyer D, Wittkowsky A. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm. 2016; 73(24):2037-41

 
 
Are you using the Digital Intern Heparin Educator? If you’d like to learn more about the Digital Intern and how it can be embedded in your Electronic Medical Record system, click here or contact us!